Aktis Oncology, Inc (AKTS)
NGS · Common · CUSIP 01021M104
Last Price•••.••
Current Yield•.••%
Yield to Call•.••%
Yield to Worst•.••%
Free registration unlocks the quote, yield calculations, price chart and full fundamentals for AKTS and every other security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Common Stock
CUSIP
01021M104
Business: Aktis Oncology, Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.

Company Contact

CEO
Matthew Roden
CFO
Kyle Kuvalanka
Headquarters
17 Drydock Avenue, Suite 17-401, Boston, MA 02210
Phone
617-461-4023
Investor Relations
Peter Vozzo ICR Healthcare · 443-213-0505 · Peter.Vozzo@icrhealthcare.com
SEC EDGAR Filings
View filings »